The impact of pneumococcal conjugate vaccines on otitis media-can we extrapolate to pneumonia?
Pneumococcal conjugate vaccines (PCVs) have significant efficacy in preventing acute otitis media caused by vaccine-type pneumococcal serotypes. This article questions whether experiences with pneumococcal otitis can be applied to pneumococcal pneumonia, and examines whether PCVs have a class effect, meaning do different PCVs offer equivalent protection against the same outcome of pneumococcal disease. While PCVs appear to have a class effect in general, variability in serotype-specific antibody concentrations makes extrapolation from one vaccine to another difficult. Antibody concentrations or measurements of antibody functionality may provide a means to anticipate a predicted outcome in pneumococcal pneumonia for certain emergent vaccine candidates.